- Home
- LENZ
as 06-30-2025 10:31am EST
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | SOLANA BEACH |
| Market Cap: | 819.1M | IPO Year: | 2021 |
| Target Price: | $41.80 | AVG Volume (30 days): | 358.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.54 - $38.93 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 544.79% |
Stock Insider Trading Activity of LENZ Therapeutics Inc. (LENZ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | LENZ | 10% Owner | Jun 10 '25 | Sell | $29.00 | 350,000 | $10,150,000.00 | 1,248,789 |
Latest LENZ Therapeutics Inc. News
LENZ Breaking Stock News: Dive into LENZ Ticker-Specific Updates for Smart Investing
Argus Research
8 days ago
Daily – Vickers Top Buyers & Sellers for 06/23/2025
GlobeNewswire
a month ago
LENZ Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
2 months ago
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
GlobeNewswire
2 months ago
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
2 months ago
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
GlobeNewswire
2 months ago
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
GlobeNewswire
3 months ago
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire
3 months ago
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Compare LENZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LENZ LENZ Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.